Advertisement
Corrigendum
Open Access | 
10.1172/JCI163716
Long noncoding RNA BLACAT2 promotes bladder cancer–associated lymphangiogenesis and lymphatic metastasis
Wang He, Guangzheng Zhong, Ning Jiang, Bo Wang, Xinxiang Fan, Changhao Chen, Xu Chen, Jian Huang, and Tianxin Lin
Find articles by He, W. in: PubMed | Google Scholar
Find articles by Zhong, G. in: PubMed | Google Scholar
Find articles by Jiang, N. in: PubMed | Google Scholar
Find articles by Wang, B. in: PubMed | Google Scholar
Find articles by Fan, X. in: PubMed | Google Scholar
Find articles by Chen, C. in: PubMed | Google Scholar
Find articles by Chen, X. in: PubMed | Google Scholar
Find articles by Huang, J. in: PubMed | Google Scholar
Find articles by Lin, T. in: PubMed | Google Scholar
Published August 15, 2022 - More info
J Clin Invest. 2022;132(16):e163716. https://doi.org/10.1172/JCI163716.
© 2022 lymphangiogenesis et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Related article:
Abstract
The prognosis for bladder cancer patients with lymph node (LN) metastasis is dismal and only minimally improved by current treatment modalities. Elucidation of the molecular mechanisms that underlie LN metastasis may provide clinical therapeutic strategies for LN-metastatic bladder cancer. Here, we report that a long noncoding RNA LINC00958, which we have termed bladder cancer–associated transcript 2 (BLACAT2), was markedly upregulated in LN-metastatic bladder cancer and correlated with LN metastasis. Overexpression of BLACAT2 promoted bladder cancer–associated lymphangiogenesis and lymphatic metastasis in both cultured bladder cancer cell lines and mouse models. Furthermore, we demonstrate that BLACAT2 epigenetically upregulated VEGF-C expression by directly associating with WDR5, a core subunit of human H3K4 methyltransferase complexes. Importantly, administration of an anti–VEGF-C antibody inhibited LN metastasis in BLACAT2-overexpressing bladder cancer. Taken together, these findings uncover a molecular mechanism in the lymphatic metastasis of bladder cancer and indicate that BLACAT2 may represent a target for clinical intervention in LN-metastatic bladder cancer.
Authors
Wang He, Guangzheng Zhong, Ning Jiang, Bo Wang, Xinxiang Fan, Changhao Chen, Xu Chen, Jian Huang, Tianxin Lin
Original citation: J Clin Invest. 2018;128(2):861–875. https://doi.org/10.1172/JCI96218
Citation for this corrigendum: J Clin Invest. 2022;132(16):e163716. https://doi.org/10.1172/JCI163716
The authors recently became aware of errors in Figure 9, B and C. In Figure 9B, the area indicated as magnified in the inset box was incorrect for the Vector/shControl/Anti-luciferase IHC image. In addition, Figure 9C contained an incorrect image for the Vector/shControl/Intratumoral sample. The corrected figure panels are shown below.
The authors regret the errors.
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)